ClinicalTrials.gg
CompletedNCT01509807IMPROVE-IRUpdated Apr 7, 2014Results posted

A Health Economic Trial in Adult Patients Undergoing Ileostomy Reversal MA402S23B504

A Phase 4 interventional study of IV morphine sulfate or Sponsor-approved equivalent and EXPAREL in Retraction of Colostomy, sponsored by Pacira Pharmaceuticals, Inc. Completed at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-04-07.

Sponsored by Pacira Pharmaceuticals, Inc · Phase 4, Interventional, and Health services research

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
33
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study is designed to compare the standard of care against EXPAREL (bupivacaine liposome injectable suspension) to determine if total opioid consumption is reduced when using EXPAREL, therefore possibly reducing total hospitalization costs.

Read the detailed description

This is a phase 4, prospective, sequential, open-label study designed to evaluate the efficacy, safety, and health economic benefits of intraoperative local wound infiltration with EXPAREL (bupivacaine liposome injectable suspension) compared with postsurgical administration of standardized intravenous (IV) morphine sulfate for postsurgical analgesia in adult patients undergoing ileostomy reversal with general anesthesia.

02

Conditions studied

  • Retraction of Colostomy

Keywords

  • Ileostomy reversal
03

In context

Lead sponsor

Pacira Pharmaceuticals, Inc is the lead sponsor of 102 studies on the registry; 3 are open to participants now.

Of its 26 completed or terminated interventional studies of FDA-regulated products, 17 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, 18 years of age and older
  • Patients scheduled to undergo ileostomy reversal
  • Ability to provide , adhere to study visit schedule, and complete all assessments.

Exclusion criteria

Exclusion Criteria:

  • Patients with a history of or idiosyncratic reactions or intolerance to any local anesthetic, opioid, or propofol.
  • Patients who abuse alcohol or other drug substance.
  • Patients with severe hepatic impairment.
  • Patients currently pregnant or who may become pregnant during the course of the study or who are unwilling to use acceptable means of for at lest one month before and one month after dosing.
  • Patients with any psychiatric, psychological, or other condition that the Investigator feels may make the patient an inappropriate candidate for this clinical study.
  • Patients who have participated in an EXPAREL study within the last 30 days.
  • Patients who have received an drug within 30 days prior to study drug administration, or planned administration of another investigational product or procedure during the patient's participation in this study.

In addition, the patient will be ineligible if he/she meets the following criteria during surgery:

  • Patients who have any concurrent surgical procedure.
  • Patients who receive intraoperative administration of opioids (other than fentanyl or analogs) or any other analgesic, local anesthetics, or anti-inflammatory agents.
  • Patients who receive Entereg(R).
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Health services research
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
33 participants (actual)

Study arms

  • Active comparator
    Group 1

    IV morphine sulfate (or Sponsor-approved equivalent), Standard of Care (SOC)

    Drug: IV morphine sulfate or Sponsor-approved equivalent

  • Experimental
    Group 2

    EXPAREL (bupivacaine liposome injectable suspension)

    Drug: EXPAREL

Interventions

  • DrugIV morphine sulfate or Sponsor-approved equivalent

    Patients enrolled in this group will receive IV morphine sulfate or Sponsor-approved equivalent via a patient-controlled analgesia (PCA) pump, as needed.

  • Patients enrolled in this group will receive 266 mg EXPAREL diluted with preservative-free 0.9% normal saline to a total volume of 30 cc and administered via wound infiltration prior to wound closure. When not contraindicated, 30 mg IV ketorolac will be given at the end of surgery. If not indicated, IV non-steroidal anti-inflammatory drug (NSAID) may be substituted per the site's standard of care.

    Also known as: bupivacaine liposome injectable suspension

06

What researchers measure

Primary outcomes

  1. Total Opioid Burden

    Total opioid consumed (IV and PO) postsurgically until hospital discharge order is written or through Day 30, whichever is sooner.

    Time frame: Wound closure to time the discharge order is written or Day 30, whichever is sooner

  2. Health Economic Benefits - Total Cost of Hospitalization

    1) Total cost of hospitalization until the time hospital discharge order is written or through Day 30, whichever is sooner.

    Time frame: Wound closure to time hospital discharge order is written or Day 30, whichever is sooner.

  3. Health Economic Benefit - Length of Stay

    Time from completion of wound closure until hospital discharge written or through Day 30, whichever was sooner

    Time frame: Wound closure to time hospital discharge order is written or Day 30, whichever is sooner.

Secondary outcomes

  1. Incidence of Opioid-related Adverse Events

    Incidence of opioid-related adverse events defined as somnolence, respiratory depression, hypoventilation, hypoxia, dry mouth, nausea, vomiting, constipation, sedation, confusion, pruritus, urinary retention, and postoperative ileus.

    Time frame: Wound closure to time hospital discharge order is written or Day 30, whichever is sooner.

  2. Patient Satisfaction With Postsurgical Analgesia

    Responses to question pertaining to patient satisfaction with postsurgical analgesia described by total percentage indicating satisfied or extremely satisfied.

    Time frame: Wound closure to time hospital discharge order is written or Day 30, whichever is sooner.

  3. Patient Discharged From the Hospital for at Least 3 Days

    Yes, if patient was discharged from the hospital for at least 3 days; no, if patient was not discharged for at least 3 day; not reported if appropriate

    Time frame: Wound closure to time hospital discharge order is written or Day 30, whichever is sooner.

  4. Readmission to Hospital Since Discharge

    Yes, if patient was readmitted to hospital since discharge; no, if patient was not readmitted to hospital since discharge; not reported, if appropriate.

    Time frame: Wound closure to time hospital discharge order is written or Day 30, whichever is sooner.

  5. Make Unplanned VIsit(s) With Any Healthcare Providers

    Yes, if patient made an unplanned visit with a healthcare provider; no, if patient did not make an unplanned visit with a healthcare provider; not reported, if applicable

    Time frame: Wound closure to time hospital discharge order is written or Day 30, whichever is sooner.

  6. Contact or Attempt to Contact Surgeon/Doctor to Discuss Recovery After Surgery

    Yes, if patient contacted or attempted to contact surgeon/doctor to discuss recovery after surgery; no, if patient did not contact or attempt contact; not reported if applicable.

    Time frame: Wound closure to time hospital discharge order is written or Day 30, whichever is sooner.

  7. Experienced Any Health Problems or Changed in Health Since Hospital Discharge

    Yes, if patient experienced any health problems or changes in health since hospital discharge; no, if patient did not experience health problems or changes since hospital discharge; not reported, if applicable.

    Time frame: Wound closure to time hospital discharge order is written or Day 30, whichever is sooner.

07

Results

Posted Apr 7, 2014

Participant flow

Participant flow — Overall Study
MilestoneGroup 1Group 2
Started1617
Completed1516
Not completed11

Outcome measures

PrimaryTotal Opioid Burden

Total opioid consumed (IV and PO) postsurgically until hospital discharge order is written or through Day 30, whichever is sooner.

Time frame:
Wound closure to time the discharge order is written or Day 30, whichever is sooner
Reported as:
Mean · mg morphine equivalent
Total Opioid Burden
mg morphine equivalentGroup 1Group 2
Total Opioid Burden112.38 ± 117.0819.8 ± 34.08
PrimaryHealth Economic Benefits - Total Cost of Hospitalization

1) Total cost of hospitalization until the time hospital discharge order is written or through Day 30, whichever is sooner.

Time frame:
Wound closure to time hospital discharge order is written or Day 30, whichever is sooner.
Reported as:
Mean · dollars
Health Economic Benefits - Total Cost of Hospitalization
dollarsGroup 1Group 2
Health Economic Benefits - Total Cost of Hospitalization9950.47 ± 3899.046728.88 ± 1874.89
SecondaryIncidence of Opioid-related Adverse Events

Incidence of opioid-related adverse events defined as somnolence, respiratory depression, hypoventilation, hypoxia, dry mouth, nausea, vomiting, constipation, sedation, confusion, pruritus, urinary retention, and postoperative ileus.

Time frame:
Wound closure to time hospital discharge order is written or Day 30, whichever is sooner.
Reported as:
Number · events
Incidence of Opioid-related Adverse Events
eventsGroup 1Group 2
Incidence of Opioid-related Adverse Events6 ± 0.824 ± 0.45
PrimaryHealth Economic Benefit - Length of Stay

Time from completion of wound closure until hospital discharge written or through Day 30, whichever was sooner

Time frame:
Wound closure to time hospital discharge order is written or Day 30, whichever is sooner.
Reported as:
Median · days
Health Economic Benefit - Length of Stay
daysGroup 1Group 2
Health Economic Benefit - Length of Stay5.1 (2.2 to 31.9)3 (0.8 to 5)
SecondaryPatient Satisfaction With Postsurgical Analgesia

Responses to question pertaining to patient satisfaction with postsurgical analgesia described by total percentage indicating satisfied or extremely satisfied.

Time frame:
Wound closure to time hospital discharge order is written or Day 30, whichever is sooner.
Reported as:
Number · percentage of patients
Patient Satisfaction With Postsurgical Analgesia
percentage of patientsGroup 1Group 2
Patient Satisfaction With Postsurgical Analgesia90.91 ± 0.6587.5 ± 0.83
SecondaryPatient Discharged From the Hospital for at Least 3 Days

Yes, if patient was discharged from the hospital for at least 3 days; no, if patient was not discharged for at least 3 day; not reported if appropriate

Time frame:
Wound closure to time hospital discharge order is written or Day 30, whichever is sooner.
Reported as:
Number · participants
Patient Discharged From the Hospital for at Least 3 Days
participantsGroup 1Group 2
Patient Discharged From the Hospital for at Least 3 Days1114
SecondaryReadmission to Hospital Since Discharge

Yes, if patient was readmitted to hospital since discharge; no, if patient was not readmitted to hospital since discharge; not reported, if appropriate.

Time frame:
Wound closure to time hospital discharge order is written or Day 30, whichever is sooner.
Reported as:
Number · participants
Readmission to Hospital Since Discharge
participantsGroup 1Group 2
Readmission to Hospital Since Discharge00
SecondaryMake Unplanned VIsit(s) With Any Healthcare Providers

Yes, if patient made an unplanned visit with a healthcare provider; no, if patient did not make an unplanned visit with a healthcare provider; not reported, if applicable

Time frame:
Wound closure to time hospital discharge order is written or Day 30, whichever is sooner.
Reported as:
Number · participants
Make Unplanned VIsit(s) With Any Healthcare Providers
participantsGroup 1Group 2
Make Unplanned VIsit(s) With Any Healthcare Providers10
SecondaryContact or Attempt to Contact Surgeon/Doctor to Discuss Recovery After Surgery

Yes, if patient contacted or attempted to contact surgeon/doctor to discuss recovery after surgery; no, if patient did not contact or attempt contact; not reported if applicable.

Time frame:
Wound closure to time hospital discharge order is written or Day 30, whichever is sooner.
Reported as:
Number · participants
Contact or Attempt to Contact Surgeon/Doctor to Discuss Recovery After Surgery
participantsGroup 1Group 2
Contact or Attempt to Contact Surgeon/Doctor to Discuss Recovery After Surgery10
SecondaryExperienced Any Health Problems or Changed in Health Since Hospital Discharge

Yes, if patient experienced any health problems or changes in health since hospital discharge; no, if patient did not experience health problems or changes since hospital discharge; not reported, if applicable.

Time frame:
Wound closure to time hospital discharge order is written or Day 30, whichever is sooner.
Reported as:
Number · participants
Experienced Any Health Problems or Changed in Health Since Hospital Discharge
participantsGroup 1Group 2
Experienced Any Health Problems or Changed in Health Since Hospital Discharge12

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group 1—1/15 (6.7%)7/15 (46.7%)
Group 2—0/17 (0%)8/17 (47.1%)
Most frequent serious events
Most frequent serious events
EventGroup 1Group 2
Gastrointestinal hemorrhageGastrointestinal disorders1/150/17
Most frequent other events
Showing 10 of 21
Most frequent other events
EventGroup 1Group 2
NauseaGastrointestinal disorders4/153/17
Abdominal distentionGastrointestinal disorders3/152/17
Fecal incontinenceGastrointestinal disorders3/150/17
VomitingGastrointestinal disorders1/153/17
Abdominal painGastrointestinal disorders2/151/17
Anal injuryInjury, poisoning and procedural complications2/150/17
DiarrheaGastrointestinal disorders1/152/17
Gastroesophageal reflux diseaseGastrointestinal disorders1/150/17
PyrexiaGeneral disorders1/150/17
InfluenzaInfections and infestations1/150/17

Baseline characteristics

One patient in Group 1 did not have the planned surgery. Thus, while 16 participants were enrolled in Group 1, 15 participants were in the Safety Analysis Set and had the planned surgery.

Age, Continuous
Age, Continuous(years)Group 1Group 2Total
Mean55.7 ± 16.0352.1 ± 15.8953.8 ± 15.8
Age, Categorical
Age, Categorical(Participants)Group 1Group 2Total
<=18 years000
Between 18 and 65 years131427
>=65 years235
Sex: Female, Male
Sex: Female, Male(Participants)Group 1Group 2Total
Female369
Male121123
Region of Enrollment
Region of Enrollment(participants)Group 1Group 2Total
United States151732
08

Study locations

3 sites
  • University of Arizona College of Medicine
    Tucson, Arizona 85724, United States
  • Florida Hospital d/b/a Colon & Rectal Surgery Center
    Orlando, Florida 32804, United States
  • University of South Florida
    Tampa, Florida 33606, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2012, a primary completion of Oct 2012 and a completion of Oct 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2014, 1 year 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 24, 2011
First posted
Jan 13, 2012
Start
Jan 2012
Primary completionActual
Oct 2012
CompletionActual
Oct 2012
Results first posted
Apr 7, 2014
Last update
Apr 7, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 7, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01509807
Collaborators
Registrat-Mapi
Responsible party
Sponsor
First posted
Jan 13, 2012
Start date
Jan 2012
Primary completion
Oct 2012
Completion
Oct 2012
Results posted
Apr 7, 2014
Last update
Apr 7, 2014

Study contacts

Jorge Marcet, MD
principal investigator · University of South Florida, Tampa, FL
Valentine Nfonsam, MD
principal investigator · University of Arizona, Tucson, AZ
Sergio Larach, MD
principal investigator · Florida Hospital, Orlando, FL.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Liposomal Bupivacaine

Start the discussion